{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-006481","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.068790+00:00","generated_at":"2026-05-15T22:28:33.800278+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioCardia reports positive echo results from Phase III HFrEF trial; reduced ventricular remodeling","bullets":["CardiAMP cell therapy reduced left ventricular end-diastolic volume (p=0.06) and end-systolic volume (p=0.09).","In patients with elevated NTproBNP, volume reductions were clinically meaningful and statistically significant (p=0.02, p=0.01).","Results correlated with reduced major adverse cardiovascular events and improved quality of life.","Echocardiography outcomes by Yale core lab; data presented at THT 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-006481","json":"https://secwatch.observer/filing/0001437749-26-006481.json","markdown":"https://secwatch.observer/filing/0001437749-26-006481.md","text":"https://secwatch.observer/filing/0001437749-26-006481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774926006481/0001437749-26-006481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774926006481/bcda20260303_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:28:33.800278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}